Holen Sie sich die Stockscreener-App
8.66
5.10%
0.42
Handel nachbörslich:
8.66
Schlusskurs vom Vortag:
$8.24
Offen:
$8.29
24-Stunden-Volumen:
800.60K
Relative Volume:
0.86
Marktkapitalisierung:
$447.24M
Einnahmen:
$742.90M
Nettoeinkommen (Verlust:
$52.60M
KGV:
10.44
EPS:
0.8295
Netto-Cashflow:
$156.80M
1W Leistung:
+10.32%
1M Leistung:
+7.31%
6M Leistung:
-4.73%
1J Leistung:
+89.08%
1-Tages-Spanne:
$8.29
$8.84
1-Wochen-Bereich:
$7.85
$8.84
52-Wochen-Spanne:
$4.44
$14.06
Emergent Biosolutions Inc Stock (EBS) Company Profile
Firmenname
Emergent Biosolutions Inc
Sektor
Telefon
240-631-3200
Adresse
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
8.66 | 411.09M | 742.90M | 52.60M | 156.80M | 0.8295 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
121.11 | 49.56B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.86B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.77 | 35.89B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
578.54 | 25.06B | 3.18B | 1.33B | 1.04B | 27.90 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-03-07 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-08-29 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-04-10 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-10 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-04-29 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-11-08 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-05-05 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Eingeleitet | The Benchmark Company | Buy |
| 2021-02-24 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-07-31 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-09-04 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | Hochstufung | Goldman | Neutral → Buy |
| 2018-08-03 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-06-13 | Eingeleitet | Argus | Buy |
| 2018-04-25 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2018-01-16 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-06-28 | Bestätigt | Singular Research | Buy |
| 2016-04-15 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-03-28 | Eingeleitet | Singular Research | Buy |
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform |
| 2014-05-15 | Eingeleitet | Summer Street Research | Buy |
| 2011-05-31 | Bestätigt | WBB Securities | Strong Buy |
| 2011-01-10 | Bestätigt | Wedbush | Outperform |
| 2010-11-05 | Bestätigt | Wedbush | Outperform |
| 2010-08-18 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | Bestätigt | Caris & Company | Buy |
Alle ansehen
Emergent Biosolutions Inc Aktie (EBS) Neueste Nachrichten
Emergent BioSolutions (EBS) price target decreased by 11.11% to 12.24 - MSN
Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness - Bioscience Association Manitoba
Emergent BioSolutions Announces Preliminary 2012 Financial Results and Provides Guidance for 2013 - AOL.com
Emergent BioSolutions Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Emergent Biosolutions partners with British Columbia to supply NARCAN nasal spray for expanded program - Traders Union
Earnings Risk: Is Emergent BioSolutions Inc stock showing strong momentum2026 Earnings Impact & Capital Efficient Trading Techniques - baoquankhu1.vn
Emergent Biosolutions Partners With British Columbia To Supply Narcan® Nasal Spray For The Launch Of The Expanded Bc Take Home Naloxone Program - TradingView — Track All Markets
Emergent BioSolutions (EBS) Partners with B.C. for Nasal Naloxone Expansion - GuruFocus
B.C. puts $18M into nasal naloxone, taps Emergent for NARCAN - Stock Titan
Dimensional Fund Advisors (EBS) reports 2.76M shares, 5.3% stake - Stock Titan
Aug Fed Impact: How does Emergent BioSolutions Inc perform in inflationary periods2026 Big Picture & Advanced Technical Analysis Signals - baoquankhu1.vn
Emergent BioSolutions Inc. (EBS) stock price, news, quote and history - Yahoo Finance UK
Emergent BioSolutions Inc. (EBS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Emergent BioSolutions (NYSE:EBS) Pulls Back 17% This Week, but Still Delivers Shareholders Strong 101% Return Over 1 Year - 富途牛牛
Emergent BioSolutions Participates in NATO Defense against Terrorism Workshop at the Counter Terror - Yahoo
Emergent Biosolutions Launches New Narcan Nasal Spray Carrying Case and Multipacks - marketscreener.com
Emergent Biosolutions expands opioid overdose preparedness with new NARCAN Nasal Spray solutions - Traders Union
Why Is Emergent BioSolutions Inc. (EBS) Stock Down Today? - Meyka
EBS PE Ratio & Valuation, Is EBS Overvalued - Intellectia AI
Insider Sell: Paul Williams Sells 4,000 Shares of Emergent BioSo - GuruFocus
Emergent BioSolutions (NYSE: EBS) SVP sells 4,000 shares - Stock Titan
Emergent Biosolutions directs 2026 Cycle A donations to public health and scientific outreach - Traders Union
Emergent BioSolutions Participates in Upcoming International Preparedness Conferences - bitget.com
Emergent joins 4 health security events from London to Kuala Lumpur - Stock Titan
[144] Emergent BioSolutions Inc. SEC Filing - Stock Titan
Chart Watch: Is Emergent BioSolutions Inc stock forming a triangle patternEarnings Performance Report & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Risks Report: Is Emergent BioSolutions Inc stock showing strong momentumShort Setup & Weekly Sector Rotation Insights - baoquankhu1.vn
Emergent BioSolutions Inc. (EBS) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Vanguard disaggregates holdings; reports zero Emergent BioSolutions stake (NYSE: EBS) - Stock Titan
Decliners Report: Can Emergent BioSolutions Inc grow without external fundingQuarterly Profit Report & Accurate Intraday Trading Signals - baoquankhu1.vn
H.C. Wainwright reiterates Emergent BioSolutions stock rating on contract wins - Investing.com Australia
H.C. Wainwright reiterates Emergent BioSolutions stock rating on contract wins By Investing.com - Investing.com South Africa
Emergent BioSolutions secures $60.6M in smallpox contracts By Investing.com - Investing.com Australia
Emergent BioSolutions secures $60M contracts - MSN
Emergent Biosolutions stock rises on $54M government contract By Investing.com - Investing.com Canada
How The Reset Price Target Is Shaping The Emergent BioSolutions (EBS) Investment Story - finance.yahoo.com
Emergent Biosolutions stock rises on $54M government contract - Investing.com
Finanzdaten der Emergent Biosolutions Inc-Aktie (EBS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.06%
1.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):